Methotrexate Accord Healthcare (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. Without tetrahydrofolate, cells cannot synthesize purines and thymidylate, the building blocks of DNA and RNA. This inhibition hampers DNA replication and cell division, particularly affecting rapidly dividing cancer cells and activated immune cells.

The specific dose of Methotrexate Accord Healthcare is determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Dosage regimens differ between oncology, rheumatology and obstetric uses, and the prescriber will tailor the amount and frequency to each individual case.

Methotrexate is classified as pregnancy category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and loss. Women of child‑bearing potential must use effective contraception. The drug is also excreted in breast milk, so breastfeeding is not recommended while receiving methotrexate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and the necessary import documentation.

Methotrexate differs from biologic agents such as TNF‑α inhibitors by acting as a small‑molecule folate antagonist that directly impairs DNA synthesis. It is often less expensive and can be administered orally or by injection, but it may require more intensive laboratory monitoring for liver and blood‑cell toxicity compared with many biologics.

Methotrexate Accord Healthcare should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

The drug can be given by intra‑arterial, intramuscular or intrathecal injection, depending on the indication and prescribing information. Administration is performed by a qualified healthcare professional in a clinical setting, following aseptic technique and the specific dosing schedule ordered by the treating physician.

Serious risks include severe liver toxicity, pulmonary fibrosis, bone‑marrow suppression leading to pancytopenia, and life‑threatening infections due to immunosuppression. Patients should be monitored regularly for liver enzymes, blood counts and respiratory symptoms, and any signs of severe toxicity require immediate medical evaluation.

Methotrexate is contraindicated in pregnant women, individuals with severe renal or hepatic impairment, and patients with known hypersensitivity to methotrexate or any of its excipients. Caution is also advised for patients with active infections, uncontrolled diabetes, or existing pulmonary disease.